List of works - Matthew J. Maurer

18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports.

scientific article

A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.

scientific article

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

scientific article

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

scientific article

A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival.

scientific article published in September 2005

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

scientific article

APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.

scientific article published on 23 October 2013

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma

scientific article published on 30 August 2019

An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.

scientific article published on June 2008

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era

Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic

scientific article

Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

scientific article published on 05 August 2019

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.

scientific article

Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 ⬇️

scientific article published on 13 March 2020

Bowel perforation in intestinal lymphoma: incidence and clinical features.

scientific article published on 22 May 2013

CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis ⬇️

scientific article published on June 28, 2013

Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas

scientific article published on 01 January 2005

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.

scientific article published on 27 June 2017

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas

scientific article published on 11 March 2019

Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study

scientific article

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

scientific article

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.

scientific article published on 28 February 2018

Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project.

scientific article

EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review

scientific article

Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors

scientific article published on 06 October 2020

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials

Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma ⬇️

scientific article published on March 7, 2011

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.

scientific article

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation ⬇️

scientific article published on February 8, 2012

Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.

scientific article published on 17 October 2011

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

scientific article

Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.

scientific article published on 10 February 2014

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

scientific article

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

scientific article published on 18 February 2014

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

scientific article published on 29 September 2017

Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma

scientific article published on 01 August 2010

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

scientific article published on 27 September 2012

FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status.

scientific article published on 3 June 2013

Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab.

scientific article published on 18 July 2017

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

scientific article

Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities

scientific article published on 3 February 2012

Germline variation in complement genes and event‐free survival in follicular and diffuse large B‐cell lymphoma ⬇️

scientific article published on June 20, 2012

High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?

scientific article published on 13 January 2020

History of autoimmune conditions and lymphoma prognosis

scientific article published on 01 August 2018

Host genetic variation in tumor necrosis factor and nuclear factor-κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study

scientific article published on 15 March 2019

Human Pegivirus infection and lymphoma risk and prognosis: a North American study

scientific article published on 29 May 2018

Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.

scientific article published on 21 July 2009

Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

scientific article published on 01 October 2019

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma

scientific article published on 28 May 2019

Implantable cardioverter defibrillator implantation rates in the Olmsted County, Minnesota, population: 1989-1999

scientific article published on 01 May 2002

Inherited determinants of ovarian cancer survival

scientific article

Inherited variants in regulatory T cell genes and outcome of ovarian cancer

scientific article

JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis

Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome

scientific article published on 27 January 2014

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

scientific article published on 01 March 2020

Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma

scientific article published on 09 October 2018

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

scientific article

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma

scientific article published on 21 December 2018

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas ⬇️

scientific article published on November 3, 2011

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

scientific article

POD24 in MZL: a means to an end or an end point in itself?

scientific article published on 01 September 2019

PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data.

scientific article

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.

scientific article published in October 2005

Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.

scientific article published in February 2005

Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes

scientific article published on 9 March 2017

Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy

scientific article published on 14 November 2019

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study

scientific article

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

scientific article published on 26 September 2005

Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma

scientific article published on 12 November 2018

Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma

scientific article published on 18 October 2013

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

scientific article published on 01 August 2018

Prospective study of quality of life in adults with newly diagnosed high-grade gliomas.

scientific article

Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients

scientific article published on 01 October 2006

Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer

scientific article

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

scientific article published on 30 September 2015

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients

scientific article published on 09 November 2020

Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era

scientific article

Survival Prediction Based on Inherited Gene Variation Analysis ⬇️

scientific article published on January 1, 2013

Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL

scientific article published on 05 March 2020

Testicular FDG-PET/CT Uptake Threshold in Aggressive Lymphomas

scientific article published on 18 December 2020

The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer

scientific article published on 14 February 2020

The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma

scientific article published on 6 September 2012

The association of health behaviors with quality of life in lymphoma survivors

scientific article published on 13 October 2020

The potential of serum light chains in diffuse large B-cell lymphoma ⬇️

scientific article published on 07 May 2013

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

scientific article

The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas

scientific article published on 10 April 2019

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

scientific article published on 07 January 2014

Utility of Progranulin and Serum Leukocyte Protease Inhibitor as Diagnostic and Prognostic Biomarkers in Ovarian Cancer ⬇️

scientific article published on July 22, 2013

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

scientific article

Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.

scientific article

List of works by Matthew J. Maurer

18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports.

A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival.

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma

An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era

Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic

Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.

Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 ⬇️

Bowel perforation in intestinal lymphoma: incidence and clinical features.

CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis ⬇️

Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas

Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.

Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project.

EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review

Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials

Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma ⬇️

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation ⬇️

Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status.

Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab.

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities

Germline variation in complement genes and event‐free survival in follicular and diffuse large B‐cell lymphoma ⬇️

High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?

History of autoimmune conditions and lymphoma prognosis

Host genetic variation in tumor necrosis factor and nuclear factor-κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study

Human Pegivirus infection and lymphoma risk and prognosis: a North American study

Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.

Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma

Implantable cardioverter defibrillator implantation rates in the Olmsted County, Minnesota, population: 1989-1999

Inherited determinants of ovarian cancer survival

Inherited variants in regulatory T cell genes and outcome of ovarian cancer

JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis

Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas ⬇️

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

POD24 in MZL: a means to an end or an end point in itself?

PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data.

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.

Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.

Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes

Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma

Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

Prospective study of quality of life in adults with newly diagnosed high-grade gliomas.

Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients

Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients

Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era

Survival Prediction Based on Inherited Gene Variation Analysis ⬇️